store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Devimistat (6,8-Bis(benzylthio)octanoic acid) 是一种线粒体代谢抑制剂,还是一种lipoic acid 拮抗剂,能阻断线粒体能量代谢,诱导多种癌细胞凋亡。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 233 | 现货 | ||
5 mg | ¥ 536 | 现货 | ||
10 mg | ¥ 728 | 现货 | ||
25 mg | ¥ 1,290 | 现货 | ||
50 mg | ¥ 2,090 | 现货 | ||
100 mg | ¥ 3,580 | 现货 | ||
500 mg | ¥ 7,780 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 637 | 现货 |
产品描述 | Devimistat (6,8-Bis(benzylthio)octanoic acid) , a lipoate analog, inhibits mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase, disrupts tumor cell mitochondrial metabolism. It has potential chemopreventive and antineoplastic activities, and has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Advanced Cancer, and Pancreatic Cancer, among others. |
体外活性 | In vitro, CPI-613 produces the selective toxicity against several tumor cell lines including H460 human lung cancer cells and Saos-2 human sarcoma cells with EC50 of 120 μM and 120 μM, respectively. CPI-613 disrupts H460 cancer cell mitochondrial metabolism including inhibition of PDH complex activity and loss of mitochondrial membrane potential in a time- and drug dose-dependent fashion. In addition, CPI-613 (240 μM) also induces both apoptotic and non-apoptotic cell death in H460 human lung cancer and Saos-2 human sarcoma cells. [1] |
体内活性 | CPI-613 (25 mg/kg) has potent anticancer activity in a human tumor xenograft model of of a pancreatic tumor cell (BxPC-3). Similarly, CPI-613 (10 mg/kg) also produces significant tumor growth inhibition of H460 human non-small cell lung carcinoma in mouse model. Besides, CPI-613 produces little or no side-effect toxicity in expected therapeutic dose ranges in large animal models and has the maximum tolerated dose of 100 mg/kg in mice. [1] |
别名 | CPI-613, 辛酸, CPI613, CPI 613, 6,8-Bis(benzylthio)octanoic acid |
分子量 | 388.59 |
分子式 | C22H28O2S2 |
CAS No. | 95809-78-2 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 78 mg/mL (200.72 mM)
DMSO: 78 mg/mL (200.72 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.5734 mL | 12.867 mL | 25.7341 mL | 64.3352 mL |
5 mM | 0.5147 mL | 2.5734 mL | 5.1468 mL | 12.867 mL | |
10 mM | 0.2573 mL | 1.2867 mL | 2.5734 mL | 6.4335 mL | |
20 mM | 0.1287 mL | 0.6434 mL | 1.2867 mL | 3.2168 mL | |
50 mM | 0.0515 mL | 0.2573 mL | 0.5147 mL | 1.2867 mL | |
100 mM | 0.0257 mL | 0.1287 mL | 0.2573 mL | 0.6434 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Devimistat 95809-78-2 Apoptosis Metabolism Dehydrogenase Mitochondrial Metabolism ipoic CPI-613 辛酸 cancer CPI613 mitochondrial CPI 613 6,8-Bis(benzylthio)octanoic acid acid inhibit abrogates Inhibitor inhibitor